News

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.
Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...
The S&P 500 Index ($SPX) (SPY) today is down -1.70%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -1.48%, and the ...
Sales of EYLEA HD rose to $393 million from $304 million a year earlier thanks to increased demand. EYLEA sales, meanwhile, declined to $754 million from $1.23 billion, which the company attributed to ...
Investing.com -- Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst ...
A tariff day blitz, pharma hit and Amazon stumble all left a cloud over Friday's stock markets as the U.S. monthly employment report is set to test faded Federal Reserve easing bets.
Regeneron (REGN) stock in focus as the company surpasses Street's Q2 projections with strong growth in high-dose Eylea, ...
Apple’s iPhone sales jump more than 13% in the tech giant’s fiscal third quarter, while Amazon stock falls on a ...
To align with global demand and the company's planned maintenance, LYB expects third quarter operating rates of 85% for North ...
During the second quarter of 2025, the Company repurchased shares of its common stock and recorded the cost of the shares, or $1.070 billion, as Treasury Stock. As of June 30, 2025, $2.814 billion ...
The Tarrytown, New York-based company said it had profit of $12.81 per share. Earnings, adjusted for one-time gains and costs, were $12.89 per share. The results exceeded Wall Street expectations. The ...
* Federal Reserve Chair Jerome Powell made it clear that the resilient U.S. labor market is currently the primary determinant ...